MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
5.98
-0.10
-1.64%
After Hours: 6.09 +0.11 +1.84% 18:43 05/09 EDT
OPEN
6.09
PREV CLOSE
6.08
HIGH
6.29
LOW
5.97
VOLUME
8.86M
TURNOVER
--
52 WEEK HIGH
12.65
52 WEEK LOW
5.82
MARKET CAP
1.84B
P/E (TTM)
-62.1622
1D
5D
1M
3M
1Y
5Y
1D
Oversold Conditions For Amicus Therapeutics (FOLD)
NASDAQ · 4d ago
Weekly Report: what happened at FOLD last week (0428-0502)?
Weekly Report · 5d ago
Amicus Therapeutics Is Maintained at Buy by UBS
Dow Jones · 05/02 22:46
Amicus Therapeutics Price Target Raised to $22.00/Share From $21.00 by UBS
Dow Jones · 05/02 22:46
UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22
Benzinga · 05/02 22:37
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
NASDAQ · 05/02 17:18
Amicus Therapeutics Is Maintained at Neutral by Goldman Sachs
Dow Jones · 05/02 16:57
Amicus Therapeutics Price Target Cut to $9.00/Share From $12.00 by Goldman Sachs
Dow Jones · 05/02 16:57
More
About FOLD
More
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Recently
Symbol
Price
%Change

Webull offers Amicus Therapeutics, Inc. stock information, including NASDAQ: FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.